What are my equipment options for taking Pulmozyme?

You have options for taking Pulmozyme (dornase alfa). The first option uses a jet nebulizer and a compressor. The second option uses a nebulizer system. Talk to your doctor about which option is right for you.

Here’s why you need a nebulizer and compressor for Pulmozyme:

  • A nebulizer changes the Pulmozyme liquid medicine into a fine mist you inhale by breathing through a mouthpiece 
  • A compressor gives the nebulizer power and makes the nebulizer work 

What are my options for taking Pulmozyme?

Several nebulizer and compressor combinations are FDA-approved for use with Pulmozyme:

Jet Nebulizers Compressors
Hudson T Up-draft II® Compressor with pressure and flow rate maximum 30 psi, 12 LPM
Marquest Acorn II®
PARI LC® Plus Compressor with pressure and flow rate maximum 24 psi, 9 LPM
Durable Sidestream® Compressor with pressure and flow rate maximum 25 psi, 7 LPM

The Pari eRapid is a fast, quiet, and portable nebulizer system option:

Nebulizer systems for Pulmozyme® (dornase alfa) administration

The eRapid system:

  • Uses mesh technology which operates differently than jet nebulizers
  • Is FDA 510 cleared for use as a general nebulizer system
  • Delivers treatment in a system that is small and portable.

Talk to your doctor about which nebulizer system is best for you and your treatment plan.

Distributors may be able to help with benefits coverage. For more information on eRapid, call PARI at (866) 335-6943, or visit PARI.com.

*Patients who are unable to inhale or exhale orally through the entire nebulization period may use the PARI BABY nebulizer.

Consisting of the eRapid® Nebulizer Handset with eBase Controller.
The average nebulization time for the eRapid Nebulizer System is approximately 2-3 minutes compared to the LC® Plus Jet Nebulizer, which is 6-10 minutes.

Take Pulmozyme on the go

Nebulizer system for Pulmozyme® (dornase alfa) administration

The Pulmozyme cooler bag was developed for patients to transport Pulmozyme when traveling or on the go. 

Patients can request one via 1-888-PLMZYME (1-888-756-9963).


What to do next?

Talk to your doctor about which equipment might be right for you

Financial assistance

Looking for financial support?

Check out the financial assistance programs available to help patients, with or without insurance

Important Safety Information

Indication and Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.